Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment

Christian J Hendriksz, Joseph Muenzer, Adeline Vanderver, Jonathan M Davis, Barbara K Burton, Nancy J Mendelsohn, Nan Wang, Luying Pan, Arian Pano, Ann J Barbier, Christian J Hendriksz, Joseph Muenzer, Adeline Vanderver, Jonathan M Davis, Barbara K Burton, Nancy J Mendelsohn, Nan Wang, Luying Pan, Arian Pano, Ann J Barbier

Abstract

In mucopolysaccharidoses (MPS), glycosaminoglycans (GAG) accumulate in tissues. In MPS II, approximately two-thirds of patients are cognitively impaired. We investigated levels of GAG in cerebrospinal fluid (CSF) in different populations from four clinical studies (including NCT00920647 and NCT01449240). Data indicate that MPS II patients with cognitive impairment have elevated levels of CSF GAG, whereas those with the attenuated phenotype typically have levels falling between those of the cognitively affected patients and healthy controls.

Keywords: Cerebrospinal fluid; Cognitive impairment; Glycosaminoglycans; Idursulfase; Inherited metabolic disease; Lysosomal storage disease; Mucopolysaccharidosis II.

Figures

Fig. 1
Fig. 1
Box plots of total CSF GAG for each subject group. Notes: 1. Surrogate normal data includes data from both the 083 study and biorepository data. 2. Values

References

    1. Bach G., Eisenberg F., Jr., Cantz M., Neufeld E.F. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc. Natl. Acad. Sci. U. S. A. 1973;70:2134–2138.
    1. Lawrence R., Brown J.R., Lorey F., Dickson P.I., Crawford B.E., Esko J.D. Glycan-based biomarkers for mucopolysaccharidoses. Mol. Genet. Metab. 2014;111:73–83.
    1. Tomatsu S., Gutierrez M.A., Ishimaru T., Pena O.M., Montano A.M., Maeda H., Velez-Castrillon S., Nishioka T., Fachel A.A., Cooper A., Thornley M., Wraith E., Barrera L.A., Laybauer L.S., Giugliani R., Schwartz I.V., Frenking G.S., Beck M., Kircher S.G., Paschke E., Yamaguchi S., Ullrich K., Isogai K., Suzuki Y., Orii T., Noguchi A. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J. Inherit. Metab. Dis. 2005;28:743–757.
    1. Tomatsu S., Okamura K., Maeda H., Taketani T., Castrillon S.V., Gutierrez M.A., Nishioka T., Fachel A.A., Orii K.O., Grubb J.H., Cooper A., Thornley M., Wraith E., Barrera L.A., Laybauer L.S., Giugliani R., Schwartz I.V., Frenking G.S., Beck M., Kircher S.G., Paschke E., Yamaguchi S., Ullrich K., Haskins M., Isogai K., Suzuki Y., Orii T., Kondo N., Creer M., Okuyama T., Tanaka A., Noguchi A. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J. Inherit. Metab. Dis. 2005;28:187–202.
    1. Jones S.A., Parini R., Harmatz P., Giugliani R., Fang J., Mendelsohn N.J. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS) Mol. Genet. Metab. 2013;109:41–48.
    1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. In: Scriver C.R., Beaudet A.L., Sly W.S., Valle D., editors. The Metabolic and Molecular Bases of Inherited Disease. III. McGraw-Hill; New York: 2001. pp. 3421–3452.
    1. Young I.D., Harper P.S., Newcombe R.G., Archer I.M. A clinical and genetic study of Hunter's syndrome. 2. Differences between the mild and severe forms. J. Med. Genet. 1982;19:408–411.
    1. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Genet. Med. 2006;8:465–473.
    1. Muenzer J., Bodamer O., Burton B., Clarke L., Frenking G.S., Giugliani R., Jones S., Rojas M.V., Scarpa M., Beck M., Harmatz P. The role of enzyme replacement therapy in severe Hunter syndrome—an expert panel consensus. Eur. J. Pediatr. 2012;171:181–188.
    1. Schutzer S.E., Liu T., Natelson B.H., Angel T.E., Schepmoes A.A., Purvine S.O., Hixson K.K., Lipton M.S., Camp D.G., Coyle P.K., Smith R.D., Bergquist J. Establishing the proteome of normal human cerebrospinal fluid. PLoS One. 2010;5
    1. Dekaban A.S., Patton V.M. Hurler's and Sanfilippo's variants of mucopolysaccharidosis. Cerebral pathology and lipid chemistry. Arch. Pathol. 1971;91:434–443.
    1. Federico A., Capece G., Cecio A., D'Auria N., Di Iorio G., Ronsisvalle L., Di Natale P. Sanfilippo B syndrome (MPS III B): case report with analysis of CSF mucopolysaccharides and conjunctival biopsy. J. Neurol. 1981;225:77–83.
    1. Munoz-Rojas M.V., Vieira T., Costa R., Fagondes S., John A., Jardim L.B., Vedolin L.M., Raymundo M., Dickson P.I., Kakkis E., Giugliani R. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am. J. Med. Genet. A. 2008;146A:2538–2544.
    1. Dickson P.I. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Int. J. Clin. Pharmacol. Ther. 2009;47(Suppl. 1):S124–S127.
    1. Muenzer J., Hendriksz C.J., Fan Z., Vijayaraghavan S., Perry V., Santra S., Solanki G.A., Mascelli M.A., Pan L., Wang N., Sciarappa K., Barbier A.J. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet. Med. 2015
    1. Hendriksz C.J., Muenzer J., Burton B.K., Pan L., Wang N., Naimy H., Pano A., Barbier A.J. A cerebrospinal fluid collection study in pediatric and adult patients with Hunter syndrome. J. Inborn Errors Metab. Screen. 2015;3
    1. Dekaban A.S., Constantopoulos G. Mucopolysaccharidoses. Relation of elevated cerebral spinal fluid to mental retardation. Arch. Neurol. 1973;28:385–388.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner